EP4335500 - METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN [Right-click to bookmark this link] | Status | The application has been published Status updated on 09.02.2024 Database last updated on 31.08.2024 | Most recent event Tooltip | 12.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Avanir Pharmaceuticals, Inc. 30 Enterprise, Suite 200 Aliso Viejo, CA 92656 / US | [2024/11] | Inventor(s) | 01 /
JOHNSON, Matt Morrisville, 27560 / US | 02 /
ZHAO, Cunxiang Tianjin, 300457 / CN | 03 /
MENG, Weihua Tianjin, 300457 / CN | 04 /
LU, Zhijun Tianjin, 300457 / CN | 05 /
LI, Yan Tianjin, 300457 / CN | [2024/11] | Representative(s) | Finnegan Europe LLP 1 London Bridge London SE1 9BG / GB | [2024/11] | Application number, filing date | 24151458.7 | 03.07.2017 | [2024/11] | Priority number, date | WO2016CN88414 | 04.07.2016 Original published format: PCT/CN2016/088414 | [2024/11] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP4335500 | Date: | 13.03.2024 | Language: | EN | [2024/11] | Type: | A3 Search report | No.: | EP4335500 | Date: | 08.05.2024 | Language: | EN | [2024/19] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 08.04.2024 | Classification | IPC: | C07D471/08 | [2024/19] | CPC: |
C07D471/08 (EP);
C07D221/28 (CN,KR,US);
C07B59/002 (KR,US);
A61K31/485 (KR);
A61P11/14 (KR);
A61P25/24 (US);
A61P25/28 (US);
C07B2200/05 (CN,US);
C07B2200/07 (CN);
C07B2200/13 (KR)
(-)
|
Former IPC [2024/11] | A61P11/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/11] | Title | German: | VERFAHREN ZUR SYNTHESE VON DEUTERIERTEM DEXTROMETHORPHAN | [2024/11] | English: | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | [2024/11] | French: | PROCÉDÉS DE SYNTHÈSE DE DEXTROMÉTHORPHANE DEUTÉRÉ | [2024/11] | Parent application(s) Tooltip | EP17740223.7 / EP3478664 | EP20203704.0 / EP3825307 | EP22181650.7 / EP4122919 | Fees paid | Renewal fee | 11.01.2024 | Renewal fee patent year 03 | 11.01.2024 | Renewal fee patent year 04 | 11.01.2024 | Renewal fee patent year 05 | 11.01.2024 | Renewal fee patent year 06 | 11.01.2024 | Renewal fee patent year 07 | 12.06.2024 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2008137474 (CONCERT PHARMACEUTICALS INC [US], et al); | [XI]WO2016040930 (AVANIR PHARMACEUTICALS INC [US]) | by applicant | US4316888 | US4446140 | US4694010 | US4806543 | US4898860 | US5166207 | US5206248 | US5304121 | US5336980 | US5350756 | US5366980 | US5863927 | US5886026 | US6099562 | US6197830 | US6207164 | US2001044446 | US2002103109 | USRE38115E | US6583152 | US2004087479 | US6803031 | US2005129783 | US2005203125 | US7014866 | US2006079502 | US2006094744 | US7114547 | US2007191411 | WO2016CN88414 |